Monoclonal gammopathy of undetermined significance: a consensus statement
James R. Berenson(Oncotherapeutics (United States)), Robert A. Kyle(Mayo Clinic), Jesús F. San Miguel(Clinica Universidad de Navarra), Sagar Lonial(Emory University), Robert A. Audell(Cedars-Sinai Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Meletios Α. Dimopoulos(Korea University), Seema Singhal(All India Institute of Medical Sciences), Ori Yellin, Eric Wirtschafter(Institute for Myeloma & Bone Cancer Research), Antonio Palumbo(University Hospital Brno), Matthew T. Drake(Hospital for Special Surgery), Rubén Niesvizky(Cornell University), Morton Coleman(Cornell University), Maurizio Zangari(University of Arkansas for Medical Sciences), Douglas Joshua(Royal Prince Alfred Hospital), Jean‐Luc Harousseau(Institut de Cancérologie de l'Ouest), Ralph V. Boccia(Center for Cancer and Blood Disorders), Rafaël Fonseca(Mayo Clinic in Arizona), Donna M. Weber(The University of Texas MD Anderson Cancer Center), G. David Roodman(Indiana University Health)
Cited by 119
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k